I completed my degree at the University of Nottingham, in Biochemistry and Biological Chemistry (MSci) in 2004.
In 2005 I moved to the University of Dundee to undertake a PhD with Professor Mike Ashford, on the role of the ß-secretase enzyme, in whole animal energy homeostasis.
Between 2009 and 2018 I worked in Professor Ashford’s lab researching the hormonal balance of energy homeostasis, type 2 diabetes and obesity.
In 2018, I was awarded a BHF Intermediate Basic Science Research Fellowship and joined the University of Leeds as a senior research fellow.
co-lead of the Physiology Society’s Metabolic Physiology Theme (2019-2022).
British Microcircualtion Society Ordinary Committee member (2019-2022).
Cardiovascular disease is the biggest cause of mortality and morbidity for individuals with Type 2 diabetes. The risk of developing Alzheimer’s disease is also significantly increased.
The aim of my lab is to understand why and how these diseases are linked, in order to find new ways to prevent their long-term harmful consequences.
Of particular interest is the ß-secretase enzyme, BACE1. We are aiming to determine the physiological and pathological functions of BACE1 and establish it as an attractive therapeutic target for Type 2 diabetes and its co-morbidities.
MSci Biochemistry and Biological chemistry
British Society for Cardiovascular Research
British Microcirculation Society
The Physiology Society
The Endocrinology Society
The Biochemistry Society
Research groups and institutes
Leeds Institute of Cardiovascular and Metabolic Medicine
Discovery and Translational Science
British Heart Foundation - Cardiovascular research
<h4>Postgraduate research opportunities</h4>
<p>We welcome enquiries from motivated and qualified applicants from all around the world who are interested in PhD study. Our <a href="https://phd.leeds.ac.uk">research opportunities</a> allow you to search for projects and scholarships.</p>
<li><a href="//phd.leeds.ac.uk/project/519-repurposing-bace1-inhibitors-for-cardiovascular-disease">Repurposing BACE1 inhibitors for cardiovascular disease</a></li>